A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder

Annals of Clinical Psychiatry

Volumn 16, Issue 3, 2004, Pages 127-132

  Crockett, Barbara A ^a   Churchill, Erik ^a   Davidson, Jonathan R T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clonazepam; Combination therapy; Obsessive compulsive disorder; Sertraline

Indexed keywords

CLONAZEPAM; PLACEBO; SERTRALINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HALLUCINATION; HUMAN; HYPOMANIA; INCREASED APPETITE; INTERVIEW; MALE; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CLONAZEPAM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 4644276714     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1080/10401230490486972     Document Type: Article

References (42)

1. Greist J, Jefferson J: Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry 1998; 173(suppl 35):65-70.
2. Jenike MA: Drug treatment of obsessive-compulsive disorders. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders. Ed. 3. St Louis, Mo: Mosby: 1998:469-523.
3. Pigott TA, Seay S: Pharmacotherapy of obsessive-compulsive disorder. Int Review Psychiatry 1997; 9:133-147.
4. Grady T, Pigott TA, L'Heureux F, Hill J, Bernstein L, Murphy D: A double-blind study of adjuvant buspirone hydrochloride in fluoxetine-treated patients with OCD. Am J Psychiatry 1993; 150: 819-821.
5. Jenike M, Baer L, Buttolph L: Buspirone augmentation of fluoxetine in patients with OCD. J Clin Psychiatry 1991; 1:13-14.
6. McDougle C, Price L, Goodman W, Charney D, Heninger G: A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11:175-184.
7. Rasmussen S: Lithium and tryptophan augmentation in clomipramine- resistant OCD. Am J Psychiatry 1984; 141:1283-1285.
8. Koran LM, Ringold AL, Elliot MA: Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000; 61(Suppl 7):514-517.
9. Iwata I, Kotani Y, Hoshino R, Takei N, Iyo M, Mori N: Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder [letter]. J Clin Psychiatry 2000; 61:528-529.
10. Cora-Locatelli G, Greenberg BD, Martin J, Murphy D: Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. J Clin Psychiatry 1998; 59(Suppl 9):480-481.
11. Fux M, Benjamin J, Belmaker RH: Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: A double-blind cross-over study. Int J Neuropsychopharmacol 1999; 2:193-195.
12. Hewlett WA, Vinogradov S, Agras WS: Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12:420-430.
13. Hewlett WA, Vinogradov S, Agras WS: Clonazepam treatment of obsessions and compulsions. J Clin Psychiatry 1990; 51:158-161.
14. Bacher NM: Clonazepam treatment of obsessive compulsive disorder [letter]. J Clin Psychiatry 1990; 4:168-169.
15. Bodkin, White K: Clonazepam in the treatment of obsessive-compulsive disorder associated with panic disorder in one patient. J Clin Psychiatry 1989; 50:265-266.
16. Jenike MA, Rauch S: Managing the patient with treatment-resistant obsessive compulsive disorder: Current strategies. J Clin Psychiatry 1994; 55(Suppl 3):11-17.
17. McDougle J: Update on pharmacologic management of OCD: Agents and augmentation. J Clin Psychiatry 1997; 58(Suppl 12):11-28.
18. Piggot TA, et al. Controlled study of clonazepam augmentation in clomipramine- or fluoxetine-treated patients with OCD. New Research Abstracts of the 145th annual meeting of the American Psychiatric Association: May 20-24, 1992; Washington DC. Abstract NR44;82
19. Hollander E, Kaplan A, Stahl S: A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry 2003; 4:30-34.
20. Stein DJ, Hollander E, Mullen LS, DeCaria CM, Liebowitz MR: Comparison of clomipramine, alprazolam, and placebo in the treatment of obsessive-compulsive disorder. Hum Psychopharmacol 1992; 7:389-395.
21. Hwang EC, Van Woert MH: Antimyoclonic action of clonazepam: The role of serotonin. Eur J Pharmacol 1979; 60:31-40.
22. Pranzatelli M: Benzodiazepine-induced shaking behavior in the rat: Structure activity and relation to serotonin and benzodiazepine receptors. Exp Neurol 1989; 104:241-250.
23. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D: Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58:681-686.
24. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association; 1994.
25. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar G: The Mini International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview. J Clin Psychiatry 1998; 59 (Suppl 20 ): 22-23.
26. Insel R, Murphy D, Cohen R, Alterman I, Kilts C, Linnoila M: Obsessive-Compulsive disorder: A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 40:605-612.
27. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR: The Yale-Brown Obsessive-Compulsive Scale, part 1: Development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006-1016.
28. Guy W (Ed.): Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, US Department of Health, Education, and Welfare. Washington, DC: Publication ADM 76-338; 1976:219-222.
29. Hamilton M: The Assessment of anxiety states by rating. Br J Med Psychol 1959; 32:10-16.
30. Hamilton M: A Rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
31. Worthington, et al. The effectiveness and safety of combined therapy with paroxetine and clonazepam compared to paroxetine alone for panic: Interim analysis. Poster session presented at the New Clinical Drug Evaluation Unit Program 39th Annual Meeting: June 1-4, 1999; Boca Raton, Fla. Poster No.6.
32. Smith WT, Londborg PD, Glaudin V, Painter JR: Extended low-dose clonazepam cotherapy of fluoxetine in the treatment of depressed outpatients. Int J Neuropsychopharmacol 2000; 3(Suppl 1):S231.
33. Johnson MR, Marazziti D, Brawman-Mintzer O, Emmanuel NP, Ware MR, Morton A, Rossi A, Cassano GB, Lydiard RB: Abnormal peripheral benzodiazepine receptor density associated with generalized social phobia. Biol Psychiatry 1998; 43(4):306-309.
34. Davidson JR: Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001; 62:46-50.
35. Rickels R, Downing R, Schweizer E, Hassman H: Anti-depressants for the treatment of generalized anxiety disorder. Arch Gen Psychiatry 1993; 50:884-894.
36. Rocca PF, Scotta M, Zanalda E, Ravizza L: Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997; 95:444-449.
37. Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY: Treatment of recent trauma survivors with benzodiazepines: A prospective study. J Clin Psychiatry 1996; 57(9):390-394.
38. Mellman TA, Byers PM, Augenstein JS: Pilot evaluation of hypnotic medication during acute traumatic stress response. J Traumatic Stress 1998; 11(3):563-569.
39. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D: Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58:681-686.
40. Diler RS, Avci A: SSRI-induced mania in obsessive compulsive disorder [letter]. J Am Acad Child Adolesc Psychiatry 1999; 38:6-7.
41. Ackerman D, Greenland S, Bystritsky A: Side effects as predictors of drug response in obsessive compulsive disorder. J Clin Psychopharmacol 1999; 5:459-465.
42. Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz MR, Lydiard B: A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995; 10(2):57-65.